The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1205
March 28, 2005
View Complete Issue         Table of Contents 2019 
Erlotinib (Tarceva) for Advanced Non-Small Cell Lung Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Erlotinib (Tarceva) for Advanced Non-Small Cell Lung Cancer
March 28, 2005 (Issue: 1205)
Erlotinib (Tarceva) is the second oral epidermal growth factor receptor (EGFR) inhibitor to become available in the US for treatment of advanced refractory NSCLC. In clinical trials, erlotinib produced a response rate of only 8.9%, but increased...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Erlotinib (Tarceva) for Advanced Non-Small Cell Lung Cancer
Article code: 1205a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.